Pharmaceutical News

RSS

HHS unveils new website on vaccine and immunization for consumers

The U.S. Department of Health and Human Services today unveiled an innovative new website to help parents and other consumers learn about the most effective way to protect themselves and their children from infectious diseases and learn about immunization.

31 Mar 2011

AA Pharma launches Lithium Carbonate SR 300mg for Bipolar Disorder in Canada

AA Pharma Inc., a leading distributor of pharmaceuticals in Canada, is pleased to announce the launch of LITHMAX, a sustained release formulation containing 300mg of lithium carbonate. LITHMAX is indicated in the treatment of manic episodes of Bipolar Disorder, as well as the maintenance treatment for individuals with a diagnosis of Bipolar Disorder.

30 Mar 2011

Traditional Chinese herbal medicine is an effective skin whitening cream

Scientists today reported discovery of the active ingredients in an herb used in traditional Chinese medicine for skin whitening, changing skin color to a lighter shade.

30 Mar 2011

McNeil takes voluntary action against certain OTC products in the U.S.

McNeil Consumer Healthcare, Division of McNEIL-PPC, Inc., is recalling one product lot of TYLENOL 8 Hour Extended Release Caplets 150 count bottles distributed in the United States.

30 Mar 2011

DSP, Intercept enter license agreement for OCA

Dainippon Sumitomo Pharma Co, Ltd. and Intercept Pharmaceuticals, Inc. today announced that they have entered into an exclusive licensing agreement for the development and commercialization of Intercept's first-in-class FXR agonist obeticholic acid.

30 Mar 2011

Dr. Reddy’s acquires GSK's US penicillin facility and products

Dr. Reddy's Laboratories today announced the completion of the acquisition of GlaxoSmithKline's United States oral penicillin facility and product portfolio pursuant to the agreement signed and announced by the companies on Nov 23, 2010.

30 Mar 2011

FDA grants orphan drug status to America Stem Cell's ASC-101

America Stem Cell, Inc. announced today that the U.S. Food and Drug Administration has granted Orphan Drug Designation to ASC-101 to improve homing to bone marrow in patients receiving hematopoietic stem cell transplantation.

30 Mar 2011

Prostate cancer drug and a new drug to prevent preterm births cause cost concerns, controversy

News outlets report on the political dilemma involved with Provenge — a cancer drug — as well as the impact that Makena — the medicine that can prevent preterm births — could have on the nation's high health care costs.

30 Mar 2011

WHO Director-General responds to draft report on agency's handling of H1N1 pandemic

WHO Director-General Margaret Chan on Monday responded to the first results of a probe into the agency's response to the H1N1 pandemic, Agence France-Presse reports.

30 Mar 2011

Unilife initiates Unifill syringe production for pharmaceutical companies

Unilife Corporation today announced it has commenced initial production of the Unifill ready-to-fill syringe at its FDA-registered manufacturing facility in York, Pennsylvania.

30 Mar 2011

Merck submits Erbitux indication extension to EMA for NSCLC treatment

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that it has submitted an indication extension to the European Medicines Agency for the approval of Erbitux in combination with standard 1st line platinum-based chemotherapy in patients with advanced or metastatic non-small cell lung cancer with high epidermal growth factor receptor expression.

30 Mar 2011

Valeant receives European Commission marketing authorization for Trobalt

Meda's partner for retigabine, Valeant Pharmaceuticals International, Inc., today announced that the European Commission has granted the marketing authorization for Trobalt™ (retigabine) in the epilepsy therapy area.

30 Mar 2011

ACCF, AHA guidelines recognize Effient as Class I treatment option for patients with ACS-PCI

Oral antiplatelet therapy Effient has been added to the updated clinical practice guidelines as a Class I recommended treatment option for patients undergoing percutaneous coronary intervention fter experiencing heart-related chest pain at rest or non-ST segment elevation myocardial infarction.

30 Mar 2011

Orthopedic surgeons prefer Genzyme's 3-cycle hyaluronic-acid in the U.S., Europe

According to a comprehensive global survey of orthopedic surgeons conducted by iData Research, the leading authority in medical device and pharmaceutical market research, orthopedic surgeons prefer 3-cycle hyaluronic-acid viscosupplementation treatment in the U.S., Europe and Latin Ameica, but are willing to try single-injection products such as Synvisc-One from Genzyme and MONOVISC from Anika Therapeutics.

30 Mar 2011

Drugs' cost deters patients from taking heart medicine

For more than 5 million Americans with heart failure, a critical step to better health is taking the medications they're prescribed. But many patients fail to do so, putting themselves at greater risk of hospitalization and even death. To date, studies have not fully answered why patients fall short when it comes to taking heart medicine. In a study appearing in the April issue of Mayo Clinic Proceedings, Mayo Clinic researchers found the drugs' cost is one of the biggest deterrents.

30 Mar 2011

USPTO grants composition-of-matter patent to Zalicus 'Synavive' product

Zalicus Inc. announced today that it has been granted a composition-of-matter patent by the U.S. Patent and Trademark office covering its product candidate Synavive.

30 Mar 2011

Non-generic drugs increase Medicaid costs

A new study by the American Enterprise Institute found that using brand-name drugs instead of generics may have added as much as $329 million in extra spending in 2009.

30 Mar 2011

USPTO issues patent to Somaxon's Silenor food effect

Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company, today announced that the U.S. Patent and Trademark Office has issued U.S. patent no. 7,915,307, entitled "Methods of Improving the Pharmacokinetics of Doxepin."

30 Mar 2011

Researchers develop new drug for multiple cancer treatment

Researchers at the University of Michigan Comprehensive Cancer Center have developed a new drug called AT-406 with potential to treat multiple types of cancer.

30 Mar 2011

EC grants marketing authorization for GSK, Valeant's Trobalt to treat epilepsy

GlaxoSmithKline and Valeant Pharmaceuticals International, Inc. announced today that the European Commission has granted marketing authorisation for Trobalt as an adjunctive treatment of partial onset seizures, with or without secondary generalisation in adults aged 18 years and above with epilepsy.

30 Mar 2011